Chlorotrianisene: Benefits, Side Effects, and Dosage

Chlorotrianisene is a non-steroidal synthetic estrogen compound that has been used for various medical applications, primarily related to the treatment of menopausal symptoms and hormonal imbalances. This comprehensive guide will explore the key aspects of Chlorotrianisene, including its medical uses, mechanism of action, pharmacokinetics, dosage, side effects, contraindications, interactions, and regulatory status.

What is Chlorotrianisene?

Chlorotrianisene, also known as TACE or NSC 10108, is a synthetic estrogen compound with a chemical structure that falls under the triphenylethylene class of compounds. Its chemical formula is C ₂₃H ₂₁ClO ₃, and it has a molecular weight of 376.87 g/mol. Chlorotrianisene is classified as a non-steroidal estrogen due to its structural similarity to diethylstilbestrol, another synthetic estrogen compound.

Medical Uses of Chlorotrianisene

Chlorotrianisene has been primarily used for the following medical applications:

1. Treatment of menopausal symptoms, such as hot flashes, night sweats, and vaginal atrophy
2. Management of estrogen deficiency and underdevelopment of female sexual characteristics
3. Hormone replacement therapy for conditions related to ovarian deficiency or ovari ectomy
4. Potential use in the treatment of certain hormone-responsive cancers, such as breast cancer, due to its antiestrogenic and partial estrogenic properties (Source)

Mechanism of Action

Chlorotrianisene exhibits both estrogenic and antiestrogenic activities, making it a selective estrogen receptor modulator (SERM). It binds to estrogen receptors and can exert partial estrogenic or antiestrogenic effects, depending on the target tissue and receptor subtype. Research studies have shown that Chlorotrianisene can stimulate the growth of hormone-responsive tissues, such as the uterus and breast, while also exhibiting anti-estrogenic effects in certain tissues, like the pituitary gland.

Pharmacokinetics and Metabolism

Chlorotrianisene is orally active and well-absorbed from the gastrointestinal tract. It undergoes extensive metabolism in the liver, where it is oxidatively converted into various metabolites. The metabolites are then excreted primarily through the kidneys. The exact half-life of Chlorotrianisene and its metabolites is not well-established, but it is considered a long-acting estrogen compound.

Dosage and Administration

Chlorotrianisene has been administered orally in various dosage forms, such as tablets or capsules. The specific dosage may vary depending on the condition being treated and the individual patient’s response. It is important to follow the dosage instructions provided by a healthcare professional and not exceed the recommended dosage, as higher doses may increase the risk of side effects.

Side Effects of Chlorotrianisene

Like other estrogen compounds, Chlorotrianisene may cause side effects, including:

• Nausea and vomiting
• Headaches
• Breast tenderness or enlargement
• Irregular vaginal bleeding or spotting
• Fluid retention and edema
• Increased risk of blood clots and stroke (especially in high doses or with prolonged use)
• Increased risk of endometrial or breast cancer with long-term use

It is important to report any severe or persistent side effects to a healthcare professional.

Contraindications and Interactions

Chlorotrianisene is contraindicated in individuals with known or suspected hormone-responsive cancers, such as breast or endometrial cancer. It should also be used with caution in pregnant or breastfeeding women, as it may harm the developing fetus or newborn baby.

Chlorotrianisene may interact with certain medications, such as anticoagulants, insulin, and other hormonal therapies. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.

Regulatory Status

The regulatory status of Chlorotrianisene may vary across different countries and regions. In the United States, it was previously approved by the FDA for certain indications but has since been discontinued for commercial use. However, it may still be used in research or investigational settings. It is essential to consult with a healthcare professional and follow the local regulations regarding the use of Chlorotrianisene.

Sources

1. ScienceDirect: Chlorotrianisene
2. PubMed: Antiestrogenic Activity of Chlorotrianisene
3. NCBI: Estrogen Receptor Modulators and Breast Cancer